NasdaqGM:IOVABiotechs
Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma
Iovance Biotherapeutics (NasdaqGM: IOVA) received conditional approval in Australia for Amtagvi, its T-cell therapy for advanced melanoma.
The Therapeutic Goods Administration decision marks the third marketing authorization for Amtagvi after the US and Canada.
Amtagvi becomes the first approved solid tumor T-cell therapy in the Australian market and is supported by an Australian treatment center.
Iovance Biotherapeutics focuses on cell therapies that use a patient's own T cells to target...


